Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) : 9 brokerage houses believe that Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a Strong Buy at current levels. 2 Analyst considers the fundamentals to be worthy of a Buy recommendation. 5 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 16 Wall Street Analysts endorse the stock as a Buy with a rating of 1.72.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) : Average target price received by Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is $115.75 with an expected standard deviation of $22.17. The most aggressive target on the stock is $155, whereas the most downbeat target is $75. 12 financial analysts are currently covering the stock.
For the current week, the company shares have a recommendation consensus of Buy. Also, Equity Analysts at the Brokerage Firm, Goldman Sachs, downgrades their rating on the shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Goldman Sachs has a Neutral rating on the shares. Previously, the analysts had a Buy rating on the shares. As per the latest research report, the brokerage house lowers the price target to $88 per share from a prior target of $109. The rating by the firm was issued on April 28, 2016.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): stock turned positive on Tuesday. Though the stock opened at $80.54, the bulls momentum made the stock top out at $83.55 level for the day. The stock recorded a low of $80.54 and closed the trading day at $83.44, in the green by 4.51%. The total traded volume for the day was 1,536,354. The stock had closed at $79.84 in the previous days trading.
In an insider trading activity, The Securities and Exchange Commission has divulged that Boger Joshua S, director of Vertex Pharmaceuticals Inc / Ma, had unloaded 5,130 shares at an average price of $87.19 in a transaction dated on June 22, 2016. The total value of the transaction was worth $447,285.
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs, including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor), Lumacaftor in combination with Ivacaftor, VX-661 in combination with Ivacaftor, VX-803, VX-970 and VX-222. The Companys product KALYDECO is available in the market.